Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (IMMVF)
OTHER OTC:IMMVF
IMMVF Stock Chart & Stats
$0.05
-$0.10(-66.67%)
At close: 4:00 PM EST
$0.05
-$0.10(-66.67%)
Day’s Range― - ―
52-Week Range$0.02 - $0.04
Previous CloseN/A
Volume500.00
Average Volume (3M)0.00
Market Cap
$12.60M
Enterprise Value-$17.97M
Total Cash (Recent Filing)$77.46M
Total Debt (Recent Filing)$857.00K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding672,666,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market Cap-1.43
Enterprise Value/Revenue-26.27
Enterprise Value/Gross Profit1.12
Enterprise Value/Ebitda0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$887.67K
Bulls Say, Bears Say
Bulls Say
Robust Clinical EvidenceMultiple peer-reviewed studies and prominent conference presentations establish durable clinical validation for PancreaSure. Strong published evidence underpins clinical utility claims, aids clinician adoption, supports payer conversations, and creates a lasting competitive moat versus less-validated diagnostics.
Broad U.S. Laboratory ApprovalsState-level approvals across 48 states (with CA approved) create structural market access enabling nationwide test ordering and processing. This reduces regulatory friction, accelerates routinized adoption by health systems, and materially lowers go-to-market barriers for scaling volumes long term.
Medicare Price And Billing Code SetHaving an established Medicare price and billing code provides a durable reimbursement framework and a reference price for other payers. This simplifies billing workflows for labs and clinicians and materially de-risks per-test revenue once formal coverage decisions are obtained.
Bears Say
Very Limited Revenue And Deep LossesRevenues remain immaterial while losses are large relative to the business scale, indicating the company has yet to demonstrate a scalable, self-sustaining diagnostic model. Persistent negative profitability undermines internal funding ability and raises the long-term risk of dilution or strategic shifts.
Negative Cash Flow And Short RunwayMaterial negative operating cash flow and a stated runway only to Q3 2026 mean the company must raise additional capital to execute commercialization and registry plans. Funding needs create dilution risk and could constrain hiring, studies, or market expansion if access to capital tightens.
Payer Coverage Not Yet SecuredAbsent formal payer coverage, realized reimbursement and collections remain uncertain despite an established price. Delays or denials in coverage decisions materially limit revenue realization, slow adoption by health systems, and increase the time and cost required to reach sustainable volumes.
Immunovia AB News
IMMVF FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was $0.02 and its highest was $0.04 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is $12.60M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Feb 24, 2026. The company reported -$0.004 earnings per share for the quarter, beating the consensus estimate of -$0.004 by <$0.001.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -$0.004 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in IMMVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMVF Company Deck
IMMVF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial, scientific and reimbursement progress: a successful product launch, strong clinical publications and podium presence, an awarded Medicare pricing of USD 897, state approvals in 48 states, targeted hiring of account managers, and a completed rights issue that improved cash position. However, near-term revenue remains limited, full payer coverage is not yet granted, cash runway extends only to Q3 2026 without additional capital, and realized per-test pricing and collections are still uncertain. The company emphasized disciplined spending, planned clinical utility data collection (including a 400-patient registry) and a mid-2026 Medicare submission with rolling data updates to mitigate coverage risk.View all IMMVF earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―